Physician Experiences with and Perceptions of Risk Evaluation and Mitigation Strategy Programs with Elements to Assure Safe Use

Interviewed physicians held mixed views on the impact of FDA risk evaluation and mitigation strategy (REMS) programs for drugs on their clinical practice, with many expressing concerns about the programs’ administrative burden and patient privacy. This suggests that while REMS programs may have positive features, they must be better integrated into clinical workflows.